Trius Therapeutics to Present Data From Drug Development Programs at ICAAC

SAN FRANCISCO — ICAAC 2012 — Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate tedizolid phosphate …

Leave a Reply

Your email address will not be published.

*